Study underscores need for early diagnostic tests in severe sepsis
US and Canadian researchers, writing in the Annals of Internal Medicine today, said they have determined that, among patients with severe manifestations of sepsis, initiation of empirical antimicrobial therapy significantly reduces the sensitivity of blood cultures drawn shortly after treatment began—underscoring the need for early diagnostic blood tests.
Administering antimicrobial agents such as antibiotics before obtaining blood cultures could decrease the time it takes for patients to receive life-saving drugs and improve outcomes—especially in patients who have severe sepsis, or an infection in the bloodstream—but scientists are unsure how this strategy affects diagnostic sensitivity.
To determine the effects of early antimicrobial initiation, the team analyzed data on 325 patients in seven North American emergency departments who had severe manifestations of sepsis. They found that 31.4% of the patients tested positive for pathogens in their blood before early antimicrobial therapy was begun, but only 19.4% tested positive afterward. The absolute difference in the proportion of positive blood cultures between pre- and post-antimicrobial testing was 12.0%, and the sensitivity of post-antimicrobial culture was only 52.9%.
The authors point out that international guidelines call for early (before-therapy) testing with suspected sepsis. "Our study has, for the first time ever, produced clear evidence supporting current sepsis guidelines and underscores the urgent need for proper sepsis protocols," said David Sweet, MD, senior study author, in a University of British Columbia news release. "Emergency rooms must place more emphasis on sepsis guidelines and make sure they have the resources to implement them."
The study was funded by Vancouver Coastal Health, St. Paul's Hospital Foundation Emergency Department Support Fund, the Fonds de recherche Sante–Quebec, and the Maricopa Medical Foundation.
Sep 17 Ann Intern Med abstract
Sep 17 University of British Columbia news release
CARB-X to fund development of novel antibiotic for gram-negatives
CARB-X announced today that it has awarded $2.2 million to UK-based Procarta Biosystems to develop a new class of antibiotics to treat dangerous gram-negative pathogens.
The money from CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) will help fund preclinical development of Procarta's lead antibiotic candidate, PRO-202, which is based on the company's novel oligonucleotide transcription factor decoy (TFD) platform. TFDs are designed to kill gram-negative and gram-positive bacteria by preventing expression of genes they need to survive and cause infection.
If successfully developed and approved, PRO-202 could be used to treat complicated urinary tract and intraabdominal infections caused by gram-negative ESKAPE pathogens (which include Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).
"CARB-X selects innovative projects that target the most serious drug-resistant bacteria and that could, if successful, be a leap forward in the fight against deadly drug-resistant superbugs," CARB-X executive director Kevin Outterson, JD, said in a press release. "The Procarta project is the type of cutting-edge innovation that can make headway against the global threat of drug-resistant bacteria."
Procarta could receive an additional $7 million if certain project milestones are met. Part of the funding comes from the UK government's Global AMR Innovation Fund.
Sep 17 CARB-X press release